Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance

Haematologica

Volumn 94, Issue 4, 2009, Pages 449-451

  Barrett, A John ^a,b   Sloand, Elaine ^a,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Department of the Allogeneic Stem Cell Transplantation   (United States)

^c Blood Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; THYMOCYTE ANTIBODY; WT1 PROTEIN;

APLASTIC ANEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CYTOPENIA; EDITORIAL; ERYTHROCYTE TRANSFUSION; GRANULOCYTE; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; QUALITY OF LIFE; REFRACTORY ANEMIA; T LYMPHOCYTE; TRISOMY 8; VACCINATION;

AUTOIMMUNITY; HUMANS; MYELODYSPLASTIC SYNDROMES; PANCYTOPENIA; T-LYMPHOCYTES; TRISOMY;

EID: 66349089112     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.006080     Document Type: Editorial

References (18)

1. Chamuleau MED, Westers TM, van Dreunen L, Groenland J, Zevenbergen A, Eeltink CM, et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009;94:496-506.
2. Okada M, Okamoto T, Takemoto Y, Kanamaru A, Kakishita E. Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities. Acta Haematol 2000; 102:124-30.
3. Mufti G, List AF, Gore SD, Ho AYL. Myelodysplastic Syndrome. Hematology 2003;2003:176-99.
4. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymo- cyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460-5.
5. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007;110:847-50.
6. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppres- sion. Blood 2002;100:3639-45.
7. Hamblin TJ. Myelodysplasia. Br J Hosp Med 1987;38:558-61.
8. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 1988;68:139-40.
9. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibi- tion of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998;102:1314-22.
10. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-11.
11. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with tri- somy 8 myelodysplastic syndrome. Blood 2005;106:841-51.
12. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004;104:4210-8.
13. Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofi- brosis. Int J Hematol 2003;78:56-61.
14. Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J, Young NS. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptot- ic markers but avoid programmed cell death by up-regula- tion of antiapoptotic proteins. Blood 2007;109:2399-405.
15. Ying L, Marino J, Hussain SP, Khan MA, You S, Hofseth AB, et al. Chronic inflammation promotes retinoblastoma pro- tein hyperphosphorylation and E2F1 activation. Cancer Res 2005;65:9132-6.
16. Goodman JE, Hofseth LJ, Hussain SP, Harris CC. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004; 44:3-9.
17. O'Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, et al. Chromosomal instability in ulcera- tive colitis is related to telomere shortening. Nat Genet 2002;32:280-4.
18. Svendsen LB, Søndergaard JO, Hegnhøj J, Højgård L, Lauritsen KB, Bülow S, et al. In vitro tetraploidy in patients with ulcerative colitis. Scand J Gastroenterol 1987;22:601-5.